On October 2, 2026, a new publication concerning terlipressin was listed in the journal Liver Transplantation, the official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. The article is titled "Vasoconstrictor therapy for HRS-AKI in patients listed for liver transplantation: Translating evidence to the pretransplant setting." This publication addresses the use of vasoconstrictor therapy in the context of hepatorenal syndrome with acute kidney injury among patients awaiting liver transplantation. Terlipressin remains an approved compound, and this publication represents newly indexed literature discussing its application in this specific pretransplant clinical setting. No results, outcomes, or efficacy data from the publication are detailed in the available event information. Readers interested in the broader regulatory and clinical context of terlipressin can refer to the compound overview for additional background.
Terlipressin: New Publication on HRS-AKI in Transplant Candidates
See the full terlipressin overview
Source: https://pubmed.ncbi.nlm.nih.gov/42825583/